Assessment of the Effect of Food on ABT-143 Bioavailability
Information source: Abbott
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pharmacokinetic Variables
Intervention: ABT-143 ( rosuvastatin calcium and fenofibric acid ) (Drug); ABT-143 (rosuvastatin calcium and fenofibric acid ) (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: Abbott Official(s) and/or principal investigator(s):
Dawn M. Carlson, MD, MPH, Study Director, Affiliation: Abbott
Overall contact:
Eilis Purcell, Phone: 847-938-3883, Email: eilis.purcell@abbott.com
Summary
Single-dose, open-label, two-period crossover study of ABT-143
Clinical Details
Study design: Basic Science, Randomized, Open Label, Crossover Assignment, Bio-availability Study
Primary outcome: Pharmacokinetics
Secondary outcome: Adverse Events
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18-55 years of age (inclusive)
- BMI 19 to 29 inclusive
Exclusion Criteria:
- Asian ancestry
- Concurrent participation in another study
- Females pregnant or breastfeeding
Locations and Contacts
Eilis Purcell, Phone: 847-938-3883, Email: eilis.purcell@abbott.com
Evansville, Indiana 47714, United States; Recruiting
Additional Information
Starting date: July 2008
Last updated: July 21, 2008
|
